ClinicalTrials.gg
CompletedNCT01318109Updated Feb 3, 2012Results posted

Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan

A Phase 2/3 interventional study of Alogliptin and metformin and Alogliptin and metformin in Type 2 Diabetes Mellitus, sponsored by Takeda. Completed. Open to participants aged 26 Years to 64 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Takeda · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
26 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 39 studies testing alogliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. alogliptin · Diabetes Mellitus, Type 2.

Enrollment
22nd of 39
288 · median 329
Started
2008
with 3 others
Phase 2/3
7 of 39
none open now
Registered
23rd of 39
by date
Lead sponsor
30 of 39
Takeda

Among the 39 studies testing alogliptin in Diabetes Mellitus, Type 2, this one is the 22nd largest by enrollment, is one of 4 that started in 2008, is one of 7 in phase 2/3, and was the 23rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About alogliptin

alogliptin: first FDA approval 2013 (NESINA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 26 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 39 studies testing alogliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.

Read the detailed description

Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.

Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.

The present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to metformin in type 2 diabetic patients who have uncontrolled blood glucose despite treatment with metformin as well as diet and exercise therapies.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Diabetes Mellitus - Type 2
  • Diabetes Mellitus
  • Drug Therapy
04

Who can participate

Ages eligible
26 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Had been taking metformin at a stable dose regimen (500 mg/day twice daily after meal or 750 mg/day three times daily after meal) for at least 12 weeks prior to the initiation of the treatment period (Week 0).
  2. Had an glycosylated () of 6.5% or more and below 10.0% at 8 weeks after the initiation of the observation period (Week -4).
  3. Had an HbA1c difference between 4 weeks after the initiation of the observation period (Week -8) and 8 weeks after the initiation of the observation period (Week -4) being within 10.0%* of the value at 4 weeks after the initiation of the observation period (Week -8) (*rounded off to the first decimal place).
  4. Was receiving specific diet and exercise (if any) therapies during the observation period.

Exclusion criteria

Exclusion Criteria:

  1. Had taken other diabetic medications than metformin within 12 weeks before the initiation of the treatment period (Week 0).
  2. With a history or symptoms of lactic acidosis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (actual)

Study arms

  • Active comparator
    Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID

    Drug: Alogliptin and metformin

  • Active comparator
    Alogliptin 25mg QD and metformin 500mg BID or 750mg TID

    Drug: Alogliptin and metformin

  • Active comparator
    Metformin 500mg BID or 750mg TID

    Drug: Metformin

Interventions

  • DrugAlogliptin and metformin

    Drug pages: Alogliptin · Metformin

    Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.

    Also known as: SYR-32, Glycoran

  • DrugAlogliptin and metformin

    Drug pages: Alogliptin · Metformin

    Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.

    Also known as: SYR-322, Glycoran

  • Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.

    Also known as: Glycoran

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (Week 12).

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.

    Time frame: Baseline and Week 12.

Secondary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin (Week 2).

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.

    Time frame: Baseline and Week 2.

  2. Change From Baseline in Glycosylated Hemoglobin (Week 4).

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.

    Time frame: Baseline and Week 4.

  3. Change From Baseline in Glycosylated Hemoglobin (Week 8).

    The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.

    Time frame: Baseline and Week 8.

  4. Change From Baseline in Fasting Plasma Glucose (Week 2).

    The change between the value of fasting plasma glucose collected at week 2 and baseline.

    Time frame: Baseline and Week 2.

  5. Change From Baseline in Fasting Plasma Glucose (Week 4).

    The change between the value of fasting plasma glucose collected at week 4 and baseline.

    Time frame: Baseline and Week 4.

  6. Change From Baseline in Fasting Plasma Glucose (Week 8).

    The change between the value of fasting plasma glucose collected at week 8 and baseline.

    Time frame: Baseline and Week 8.

  7. Change From Baseline in Fasting Plasma Glucose (Week 12).

    The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.

    Time frame: Baseline and Week 12.

  8. Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).

    The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

    Time frame: Baseline and Week 12.

07

Results

Posted Jul 11, 2011

Participant flow

Participants enrolled at 30 investigative sites in Japan from 22 August 2008 to 28 April 2009.

Participant flow — Overall Study
MilestoneAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Started9296100
Completed9193100
Not completed130
Withdrew: Adverse event020
Withdrew: Withdrawal by subject100
Withdrew: Schedule conflict010

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin (Week 12).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.

Time frame:
Baseline and Week 12.
Reported as:
Mean · percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 12).
percentage of Glycosylated HemoglobinAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Glycosylated Hemoglobin (Week 12).-0.54 ± 0.562-0.64 ± 0.4880.21 ± 0.641
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.751 · 95% CI -0.923 to -0.579
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.858 · 95% CI -1.019 to -0.697
SecondaryChange From Baseline in Glycosylated Hemoglobin (Week 2).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.

Time frame:
Baseline and Week 2.
Reported as:
Mean · percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 2).
percentage of Glycosylated HemoglobinAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Glycosylated Hemoglobin (Week 2).-0.13 ± 0.196-0.13 ± 0.1500.06 ± 0.197
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.191 · 95% CI -0.247 to -0.135
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.192 · 95% CI -0.242 to -0.143
SecondaryChange From Baseline in Glycosylated Hemoglobin (Week 4).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.

Time frame:
Baseline and Week 4.
Reported as:
Mean · percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 4).
percentage of Glycosylated HemoglobinAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Glycosylated Hemoglobin (Week 4).-0.29 ± 0.279-0.31 ± 0.2680.09 ± 0.302
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Hazard ratio, log: -0.386 · 95% CI -0.469 to -0.303
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.403 · 95% CI -0.484 to -0.323
SecondaryChange From Baseline in Glycosylated Hemoglobin (Week 8).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.

Time frame:
Baseline and Week 8.
Reported as:
Mean · percentage of Glycosylated Hemoglobin
Change From Baseline in Glycosylated Hemoglobin (Week 8).
percentage of Glycosylated HemoglobinAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Glycosylated Hemoglobin (Week 8).-0.49 ± 0.488-0.56 ± 0.4040.13 ± 0.465
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -0.621 · 95% CI -0.757 to -0.486
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Hazard ratio, log: -0.692 · 95% CI -0.814 to -0.569
SecondaryChange From Baseline in Fasting Plasma Glucose (Week 2).

The change between the value of fasting plasma glucose collected at week 2 and baseline.

Time frame:
Baseline and Week 2.
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 2).
mg/dLAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Fasting Plasma Glucose (Week 2).-19.2 ± 21.10-23.2 ± 24.170.0 ± 26.37
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -19.26 · 95% CI -26.12 to -12.40
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -23.27 · 95% CI -30.43 to -16.12
SecondaryChange From Baseline in Fasting Plasma Glucose (Week 4).

The change between the value of fasting plasma glucose collected at week 4 and baseline.

Time frame:
Baseline and Week 4.
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 4).
mg/dLAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Fasting Plasma Glucose (Week 4).-19.8 ± 25.28-23.5 ± 26.05-2.2 ± 23.37
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -17.60 · 95% CI -24.54 to -10.66
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -21.35 · 95% CI -28.32 to -14.39
SecondaryChange From Baseline in Fasting Plasma Glucose (Week 8).

The change between the value of fasting plasma glucose collected at week 8 and baseline.

Time frame:
Baseline and Week 8.
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 8).
mg/dLAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Fasting Plasma Glucose (Week 8).-22.0 ± 23.05-21.3 ± 25.30-3.1 ± 26.23
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -18.87 · 95% CI -25.95 to -11.79
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -18.16 · 95% CI -25.43 to -10.90
SecondaryChange From Baseline in Fasting Plasma Glucose (Week 12).

The change between the value of fasting plasma glucose collected at week 12 or final visit and baseline.

Time frame:
Baseline and Week 12.
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (Week 12).
mg/dLAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Fasting Plasma Glucose (Week 12).-19.0 ± 23.23-23.1 ± 27.84-0.8 ± 32.20
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -18.24 · 95% CI -26.32 to -10.16
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -22.38 · 95% CI -30.87 to -13.88
SecondaryChange From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).

The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and at 2 hours after the start of the meal.

Time frame:
Baseline and Week 12.
Reported as:
Mean · mg/dL
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).
mg/dLAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).61.7 ± 43.4264.2 ± 34.7670.6 ± 35.31
Statistical analysis
  • Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -8.89 · 95% CI -20.14 to 2.37
  • Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID vs Metformin 500mg BID or 750mg TID · Mean difference (final values): -6.41 · 95% CI -16.34 to 3.52

Adverse events

Collected over Treatment-emergent adverse events are any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 30 days after receiving the last dose of study drug.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TID—0/92 (0%)32/92 (34.8%)
Alogliptin 25mg QD and Metformin 500mg BID or 750mg TID—2/96 (2.1%)37/96 (38.5%)
Metformin 500mg BID or 750mg TID—0/100 (0%)29/100 (29%)
Most frequent serious events
Most frequent serious events
EventAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/921/960/100
Mallory-Weiss syndromeGastrointestinal disorders0/921/960/100
Most frequent other events
Most frequent other events
EventAlogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TID
NasopharyngitisInfections and infestations18/9222/9620/100
HeadacheNervous system disorders6/920/960/100
DiarrhoeaGastrointestinal disorders5/921/961/100
ConstipationGastrointestinal disorders1/924/962/100
Conjunctivitis allergicEye disorders1/923/961/100
Abdominal discomfortGastrointestinal disorders1/923/961/100
Hepatic steatosisHepatobiliary disorders0/923/961/100
Blood lactic acid increasedInvestigations0/921/963/100

Baseline characteristics

Age Continuous
Age Continuous(years)Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TIDTotal
Mean53.4 ± 8.8052.3 ± 8.0252.1 ± 8.0552.6 ± 8.28
Sex: Female, Male
Sex: Female, Male(Participants)Alogliptin 12.5 mg QD and Metformin 500mg BID or 750mg TIDAlogliptin 25mg QD and Metformin 500mg BID or 750mg TIDMetformin 500mg BID or 750mg TIDTotal
Female32302890
Male606672198
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2011
First posted
Mar 18, 2011
Start
Aug 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jul 11, 2011
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01318109
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 18, 2011
Start date
Aug 2008
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jul 11, 2011
Last update
Feb 3, 2012

Study contacts

Professor, Diabetes and Endocrine Division
study director · Department of Medicine, Kawasaki Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alogliptin · Metformin

Start the discussion